{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T08:52:43Z","timestamp":1788079963152,"version":"build-2784847793"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.semcancer.2020.12.008","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T21:20:07Z","timestamp":1611004807000},"page":"197-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism"],"prefix":"10.1016","volume":"79","author":[{"given":"Alessio","family":"Basolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4263-4717","authenticated-orcid":false,"given":"Antonio","family":"Matrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Elisei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1706-0822","authenticated-orcid":false,"given":"Ferruccio","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semcancer.2020.12.008_bib0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Du","year":"2018","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2020.12.008_bib0010","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell Signaling by Receptor Tyrosine Kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.semcancer.2020.12.008_bib0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell Signaling by Receptor Tyrosine Kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.semcancer.2020.12.008_bib0020","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1073\/pnas.77.3.1311","article-title":"Transforming gene product of Rous sarcoma virus phosphorylates tyrosine","volume":"77","author":"Hunter","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.semcancer.2020.12.008_bib0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12943-018-0792-2","article-title":"Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors","volume":"17","author":"Montor","year":"2018","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2020.12.008_bib0030","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.semcancer.2020.12.008_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/370835","article-title":"Evasion of apoptosis as a cellular stress response in cancer","volume":"2010","author":"Fulda","year":"2010","journal-title":"Int. J. Cell Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.12.008_bib0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0045","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/jcb.21707","article-title":"Dysregulation of apoptotic signaling in Cancer: molecular mechanisms and therapeutic opportunities","volume":"104","author":"Plati","year":"2008","journal-title":"J. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.semcancer.2020.12.008_bib0050","first-page":"152","article-title":"Autocrine growth factors and solid tumor malignancy","volume":"155","author":"Walsh","year":"1991","journal-title":"West. J. Med."},{"issue":"7","key":"10.1016\/j.semcancer.2020.12.008_bib0055","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/nm.2819","article-title":"Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia","volume":"18","author":"Kentsis","year":"2012","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0060","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ng1215","article-title":"Chromosome aberrations in solid tumors","volume":"34","author":"Albertson","year":"2003","journal-title":"Nat. Genet."},{"issue":"Suppl 1","key":"10.1016\/j.semcancer.2020.12.008_bib0065","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-2164-11-S1-S1","article-title":"Mechanisms of chromosomal rearrangement in the human genome","volume":"11","author":"Tsai","year":"2010","journal-title":"BMC Genomics"},{"issue":"6","key":"10.1016\/j.semcancer.2020.12.008_bib0070","first-page":"856","article-title":"New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile","volume":"23","author":"Lopez-Gines","year":"2010","journal-title":"Mod. Pathol. Off. J. US Can. Acad. Pathol. Inc."},{"issue":"1","key":"10.1016\/j.semcancer.2020.12.008_bib0075","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/annonc\/mdh011","article-title":"Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer","volume":"15","author":"Selvaggi","year":"2004","journal-title":"Ann Oncol Off. J. Eur. Soc. Med. Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2020.12.008_bib0080","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.tig.2006.06.007","article-title":"Gene amplification in cancer","volume":"22","author":"Albertson","year":"2006","journal-title":"Trends. Genet. TIG"},{"issue":"6127","key":"10.1016\/j.semcancer.2020.12.008_bib0085","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.semcancer.2020.12.008_bib0090","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/nsmb.2168","article-title":"Mechanistic insights into the activation of oncogenic forms of EGF receptor","volume":"18","author":"Wang","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"3","key":"10.1016\/j.semcancer.2020.12.008_bib0095","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2020.12.008_bib0100","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.tibs.2019.03.009","article-title":"An emerging advantage for Cancer biology","volume":"44","author":"Li","year":"2019","journal-title":"Trends Biochem. Sci."},{"issue":"3","key":"10.1016\/j.semcancer.2020.12.008_bib0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030731","article-title":"Tyrosine kinase inhibitors in Cancer: breakthrough and challenges of targeted therapy","volume":"12","author":"Pottier","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2020.12.008_bib0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.semcancer.2020.12.008_bib0115","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ando.2018.07.011","article-title":"Expert opinion on the metabolic complications of new anticancer therapies: tyrosine kinase inhibitors","volume":"79","author":"Buffier","year":"2018","journal-title":"Ann. Endocrinol. (Paris)"},{"key":"10.1016\/j.semcancer.2020.12.008_bib0120","series-title":"Tyrosine Kinases Druggable Targets Cancer","article-title":"Cancer management by tyrosine kinase inhibitors: efficacy, limitation, and future strategies","author":"Ho","year":"2019"},{"issue":"3","key":"10.1016\/j.semcancer.2020.12.008_bib0125","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers12030731","article-title":"Tyrosine kinase inhibitors in Cancer: breakthrough and challenges of targeted therapy","volume":"12","author":"Pottier","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0130","first-page":"113","article-title":"Side effects of tyrosine kinase inhibitors \u2014 management guidelines","volume":"12","author":"P\u0142u\u017ca\u0144ski","year":"2016","journal-title":"Oncol. Clin. Pract."},{"issue":"5","key":"10.1016\/j.semcancer.2020.12.008_bib0135","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr. Drug Metab."},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0140","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11906-007-0058-7","article-title":"Chemotherapy agents and hypertension: a focus on angiogenesis blockade","volume":"9","author":"Jain","year":"2007","journal-title":"Curr. Hypertens. Rep."},{"issue":"24","key":"10.1016\/j.semcancer.2020.12.008_bib0145","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.12.008_bib0150","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7555\/JBR.32.20170080","article-title":"Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma: a meta-analysis","volume":"32","author":"Qin","year":"2018","journal-title":"J. Biomed. Res."},{"issue":"2","key":"10.1016\/j.semcancer.2020.12.008_bib0155","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-007-9860-9","article-title":"Pooled analysis of diarrhea events in patients with cancer treated with lapatinib","volume":"112","author":"Crown","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.semcancer.2020.12.008_bib0160","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/SPC.0b013e32835ec861","article-title":"Mechanisms of TKI-induced diarrhea in cancer patients","volume":"7","author":"Bowen","year":"2013","journal-title":"Curr. Opin. Support. Palliat. Care"},{"issue":"2","key":"10.1016\/j.semcancer.2020.12.008_bib0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2012.09.004","article-title":"Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis","volume":"39","author":"Teo","year":"2013","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.semcancer.2020.12.008_bib0170","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3747\/co.v18i3.877","article-title":"Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer","volume":"18","author":"Hirsh","year":"2011","journal-title":"Curr. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0175","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/jjco\/hyv207","article-title":"Skin problems and EGFR-tyrosine kinase inhibitor","volume":"46","author":"Kozuki","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2020.12.008_bib0180","first-page":"8","article-title":"Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1","author":"Omote","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.semcancer.2020.12.008_bib0185","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4143\/crt.2014.201","article-title":"Gefitinib-induced interstitial lung disease in Korean lung cancer patients","volume":"48","author":"Beom","year":"2016","journal-title":"Cancer Res. Treat."},{"issue":"9","key":"10.1016\/j.semcancer.2020.12.008_bib0190","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12032-014-0147-9","article-title":"Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres","volume":"31","author":"Ivanyi","year":"2014","journal-title":"Med. Oncol. Northwood. Lond. Engl."},{"issue":"8","key":"10.1016\/j.semcancer.2020.12.008_bib0195","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1210\/jc.2016-4025","article-title":"Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma","volume":"102","author":"Beukhof","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0200","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1089\/thy.2017.0587","article-title":"Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers","volume":"28","author":"Lechner","year":"2018","journal-title":"Thyroid. Off J. Am. Thyroid. Assoc."},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0205","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3109\/0284186X.2012.752579","article-title":"Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis","volume":"52","author":"Funakoshi","year":"2013","journal-title":"Acta. Oncol. Stockh. Swed."},{"issue":"3","key":"10.1016\/j.semcancer.2020.12.008_bib0210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-08-0648","article-title":"Tyrosine kinase inhibitors and modifications of thyroid function tests: a review","volume":"160","author":"Illouz","year":"2009","journal-title":"Eur. J. Endocrinol."},{"issue":"11","key":"10.1016\/j.semcancer.2020.12.008_bib0215","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/thy.2010.0251","article-title":"Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia","volume":"20","author":"Kim","year":"2010","journal-title":"Thyroid. Off J. Am. Thyroid. Assoc."},{"issue":"9","key":"10.1016\/j.semcancer.2020.12.008_bib0220","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1586\/14737140.2014.929501","article-title":"Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis","volume":"14","author":"Abdel-Rahman","year":"2014","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.semcancer.2020.12.008_bib0225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2019.05.015","article-title":"Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders","volume":"141","author":"Jannin","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.12.008_bib0230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1620\/tjem.222.39","article-title":"Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume","volume":"222","author":"Sakurai","year":"2010","journal-title":"Tohoku J. Exp. Med."},{"issue":"10","key":"10.1016\/j.semcancer.2020.12.008_bib0235","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid Off J. Am. Thyroid. Assoc."},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0240","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/archinte.1980.00330160038023","article-title":"Lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis)","volume":"140","author":"Nikolai","year":"1980","journal-title":"Arch. Intern. Med."},{"issue":"9","key":"10.1016\/j.semcancer.2020.12.008_bib0245","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"Desai","year":"2006","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2020.12.008_bib0250","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2020.12.008_bib0255","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.e16097","article-title":"Efficacy and thyroidal effects of sunitinib in Japanese patients with metastatic renal cell carcinoma: hypothyroidism and thyroid atrophy as potential biomarkers for sunitinib?","volume":"27","author":"Shinohara","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2020.12.008_bib0260","first-page":"723","article-title":"Thyroid dysfunctions induced by tyrosine kinase inhibitors","volume":"13","author":"Fallahi","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"issue":"26","key":"10.1016\/j.semcancer.2020.12.008_bib0265","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1056\/NEJMra021194","article-title":"Thyroiditis","volume":"348","author":"Pearce","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2020.12.008_bib0270","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/thy.2009.0125","article-title":"Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?","volume":"20","author":"Rogiers","year":"2010","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"issue":"2","key":"10.1016\/j.semcancer.2020.12.008_bib0275","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature","volume":"290","author":"Kamba","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"10.1016\/j.semcancer.2020.12.008_bib0280","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/thy.2009.0414","article-title":"Sunitinib induces hypothyroidism with a markedly reduced vascularity","volume":"20","author":"Makita","year":"2010","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"issue":"10","key":"10.1016\/j.semcancer.2020.12.008_bib0285","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/jc.2011-1172","article-title":"Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary Regression","volume":"96","author":"Kappers","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.semcancer.2020.12.008_bib0290","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/thy.2015.0170","article-title":"Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?","volume":"25","author":"Pani","year":"2015","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0295","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/thy.2012.0378","article-title":"Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib","volume":"23","author":"Ohba","year":"2013","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"issue":"8","key":"10.1016\/j.semcancer.2020.12.008_bib0300","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jjco\/hys076","article-title":"Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma","volume":"42","author":"Daimon","year":"2012","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0305","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2265.2008.03253.x","article-title":"Thyrotoxicosis during sunitinib treatment for renal cell carcinoma","volume":"69","author":"Grossmann","year":"2008","journal-title":"Clin. Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.semcancer.2020.12.008_bib0310","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.urolonc.2009.08.011","article-title":"Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation","volume":"28","author":"Miyake","year":"2010","journal-title":"Urol. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2020.12.008_bib0315","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/thy.2010.0234","article-title":"Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma","volume":"21","author":"van Doorn","year":"2011","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.semcancer.2020.12.008_bib0320","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s12328-020-01107-6","article-title":"Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma","volume":"13","author":"Suoh","year":"2020","journal-title":"Clin. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.semcancer.2020.12.008_bib0325","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2169\/internalmedicine.1874-18","article-title":"Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma","volume":"58","author":"Hirooka","year":"2019","journal-title":"Intern. Med."},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0330","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2009.4","article-title":"Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy","volume":"6","author":"Torino","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0335","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/thy.2006.0308","article-title":"Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity","volume":"17","author":"Wong","year":"2007","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"issue":"2","key":"10.1016\/j.semcancer.2020.12.008_bib0340","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/thy.2012.0456","article-title":"Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis","volume":"23","author":"Makita","year":"2013","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"issue":"1","key":"10.1016\/j.semcancer.2020.12.008_bib0345","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","article-title":"Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Rini","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.semcancer.2020.12.008_bib0350","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1089\/thy.2013.0621","article-title":"Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma","volume":"24","author":"Yavuz","year":"2014","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"issue":"9","key":"10.1016\/j.semcancer.2020.12.008_bib0355","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","article-title":"A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake","volume":"92","author":"Mannavola","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.semcancer.2020.12.008_bib0360","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1089\/thy.2014.0006","article-title":"Sunitinib does not block thyroid peroxidase in patients","volume":"24","author":"Liwanpo","year":"2014","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0365","article-title":"Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients","volume":"34","author":"Buda-Nowak","year":"2017","journal-title":"Med. Oncol. Northwood Lond Engl"},{"issue":"6","key":"10.1016\/j.semcancer.2020.12.008_bib0370","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00345-010-0627-2","article-title":"Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib","volume":"29","author":"Riesenbeck","year":"2011","journal-title":"World J. Urol."},{"issue":"3","key":"10.1016\/j.semcancer.2020.12.008_bib0375","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cncr.25422","article-title":"Hypothyroidism in patients with renal cell carcinoma: blessing or curse?","volume":"117","author":"Schmidinger","year":"2011","journal-title":"Cancer"},{"issue":"29","key":"10.1016\/j.semcancer.2020.12.008_bib0380","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J. Clin. Oncol Off. J. Am. Soc. Clin. Oncol"},{"issue":"7","key":"10.1016\/j.semcancer.2020.12.008_bib0385","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2020.12.008_bib0390","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.semcancer.2020.12.008_bib0395","doi-asserted-by":"crossref","first-page":"7606","DOI":"10.1002\/anie.201601116","article-title":"Chemistry and biology in the biosynthesis and action of thyroid hormones","volume":"55","author":"Mondal","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"10","key":"10.1016\/j.semcancer.2020.12.008_bib0400","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1172\/JCI29812","article-title":"Deiodinases: implications of the local control of thyroid hormone action","volume":"116","author":"Bianco","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.semcancer.2020.12.008_bib0405","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41574-019-0218-2","article-title":"Deiodinases and their intricate role in thyroid hormone homeostasis","volume":"15","author":"Luongo","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6308","key":"10.1016\/j.semcancer.2020.12.008_bib0410","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/349438a0","article-title":"Type I iodothyronine deiodinase is a selenocysteine-containing enzyme","volume":"349","author":"Berry","year":"1991","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.semcancer.2020.12.008_bib0415","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1210\/en.2004-1392","article-title":"Type 1 iodothyronine deiodinase is a sensitive marker of peripheral thyroid status in the mouse","volume":"146","author":"Zavacki","year":"2005","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0420","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1172\/JCI110854","article-title":"Evidence for two pathways of iodothyronine 5\u2019-deiodination in rat pituitary that differ in kinetics, propylthiouracil sensitivity, and response to hypothyroidism","volume":"71","author":"Visser","year":"1983","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.semcancer.2020.12.008_bib0425","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1530\/eje.0.1440577","article-title":"Evidence for a role of the type III-iodothyronine deiodinase in the regulation of 3, 5, 3\u2019-triiodothyronine content in the human central nervous system","volume":"144","author":"Santini","year":"2001","journal-title":"Eur. J. Endocrinol."},{"issue":"6","key":"10.1016\/j.semcancer.2020.12.008_bib0430","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1210\/jc.2002-021439","article-title":"Role for inner ring deiodination preventing transcutaneous passage of thyroxine","volume":"88","author":"Santini","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.semcancer.2020.12.008_bib0435","first-page":"1366","article-title":"Evidence that the human placental 5-monodeiodinase is a phospholipid-requiring enzyme","volume":"74","author":"Santini","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.semcancer.2020.12.008_bib0440","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1089\/thy.2005.15.875","article-title":"Physiology and pathophysiology of type 3 deiodinase in humans","volume":"15","author":"Huang","year":"2005","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"issue":"5","key":"10.1016\/j.semcancer.2020.12.008_bib0445","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1172\/JCI118299","article-title":"Type 3 lodothyronine deiodinase: cloning, in vitro expression, and functional analysis of the placental selenoenzyme","volume":"96","author":"Salvatore","year":"1995","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0450","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clpt.2005.06.010","article-title":"Plukker JTM, van Der Graaf WTA, Links TP. Imatinib induces hypothyroidism in patients receiving levothyroxine","volume":"78","author":"de Groot","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.semcancer.2020.12.008_bib0455","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/annonc\/mdl112","article-title":"Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine","volume":"17","author":"de Groot","year":"2006","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.12.008_bib0460","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"Motesanib diphosphate in progressive differentiated thyroid cancer","volume":"359","author":"Sherman","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"29","key":"10.1016\/j.semcancer.2020.12.008_bib0465","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol"},{"issue":"8","key":"10.1016\/j.semcancer.2020.12.008_bib0470","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1210\/jc.2009-2507","article-title":"Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination","volume":"95","author":"Abdulrahman","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.semcancer.2020.12.008_bib0475","first-page":"493","article-title":"Serum iodothyronines in the human fetus and the newborn: evidence for an important role of placenta in fetal thyroid hormone homeostasis","volume":"84","author":"Santini","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"14","key":"10.1016\/j.semcancer.2020.12.008_bib0480","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1308893","article-title":"Thyroid hormone inactivation in gastrointestinal stromal tumors","volume":"370","author":"Maynard","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2020.12.008_bib0485","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJM200007203430305","article-title":"Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas","volume":"343","author":"Huang","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.semcancer.2020.12.008_bib0490","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1089\/thy.2005.15.1369","article-title":"Consumptive hypothyroidism caused by paraneoplastic production of type 3 iodothyronine deiodinase","volume":"15","author":"Ruppe","year":"2005","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"issue":"3","key":"10.1016\/j.semcancer.2020.12.008_bib0495","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.beem.2017.06.001","article-title":"Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life","volume":"31","author":"Matrone","year":"2017","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0500","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1210\/er.2018-00275","article-title":"Paradigms of dynamic control of thyroid hormone signaling","volume":"40","author":"Bianco","year":"2019","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.semcancer.2020.12.008_bib0505","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1210\/jc.2011-1837","article-title":"Tyrosine kinase inhibitors noncompetitively inhibit MCT8-Mediated iodothyronine transport","volume":"97","author":"Braun","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.semcancer.2020.12.008_bib0510","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1210\/edrv.22.4.0435","article-title":"Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability","volume":"22","author":"Hennemann","year":"2001","journal-title":"Endocr. Rev."},{"issue":"41","key":"10.1016\/j.semcancer.2020.12.008_bib0515","doi-asserted-by":"crossref","first-page":"40128","DOI":"10.1074\/jbc.M300909200","article-title":"Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter","volume":"278","author":"Friesema","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.semcancer.2020.12.008_bib0520","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nrendo.2015.66","article-title":"Thyroid hormone transporters--functions and clinical implications","volume":"11","author":"Bernal","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"issue":"2","key":"10.1016\/j.semcancer.2020.12.008_bib0525","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/EJE-12-0828","article-title":"Sorafenib therapy decreases the clearance of thyrotropin","volume":"168","author":"Verloop","year":"2013","journal-title":"Eur. J. Endocrinol."},{"issue":"6359","key":"10.1016\/j.semcancer.2020.12.008_bib0530","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/355446a0","article-title":"Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling","volume":"355","author":"Kliewer","year":"1992","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.semcancer.2020.12.008_bib0535","doi-asserted-by":"crossref","first-page":"e0147048","DOI":"10.1371\/journal.pone.0147048","article-title":"Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses","volume":"11","author":"Shu","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.semcancer.2020.12.008_bib0540","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/ERC-19-0259","article-title":"Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response","volume":"27","author":"Valerio","year":"2020","journal-title":"Endocr. Relat. Cancer"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X20302686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X20302686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:51:17Z","timestamp":1760917877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X20302686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":108,"alternative-id":["S1044579X20302686"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2020.12.008","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2020.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}